Introducing the MPN-RC Team working on a mission to cure Myelofibrosis.
The Myeloproliferative Neoplasms Research Consortium (MPN-RC) is an inter-active group of laboratory scientists, clinical scientists, and a biostatistics team, who work in coordination to develop and evaluate treatments that will improve the survival of patients with myeloproliferative neoplasms (MPN). The overall goal of the MPN-RC is to merge the skills and efforts of its scientifically diverse membership to generate the scientific foundation for novel therapeutic strategies which will be evaluated in rigorous, well- constructed independent investigator-initiated clinical trials. The MPN-RC, formerly MPD-RC, opened its first trial over a decade ago. Investigators from over 30 institutions in the US, Canada, Europe, and Israel had treated over 300 patients diagnosed with myelofibrosis, polycythemia vera, thrombocythemia, and acute myeloid leukemia. Currently, the MPN-RC has investigators in 11 institutions around the US and in Canada.
The MPN-RC program has eight major projects.
The program, developed with the efforts of all the members of the Consortium, consists of basic, translational and clinical studies. All of the projects are considered highly meritorious, very strong in preliminary data and research design, and with great potential to produce significant results.
Molecular Pathogenesis and Therapy of Myeloproliferative NeoplasmsView Project Details
Defining the Role of Megakaryocyte Abnormalties in the Progression of Primary MyelofibrosisView Project Details
Development of Strategies to Deplete Myelofibrosis Stem CellsView Project Details
Mayo Clinic Arizona
Cleveland Clinic Lerner College of Medicine of CWRU
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Sloan Kettering Institute for Cancer Research
The Regents of the University of Michigan
University Health Network
University of Kansas Medical Center
Wake Forest University Health Sciences
UT Health San Antonio
Cedars Sinai Medical Center